JP2016519107A5 - - Google Patents

Download PDF

Info

Publication number
JP2016519107A5
JP2016519107A5 JP2016507634A JP2016507634A JP2016519107A5 JP 2016519107 A5 JP2016519107 A5 JP 2016519107A5 JP 2016507634 A JP2016507634 A JP 2016507634A JP 2016507634 A JP2016507634 A JP 2016507634A JP 2016519107 A5 JP2016519107 A5 JP 2016519107A5
Authority
JP
Japan
Prior art keywords
hypoxia
predetermined value
cancer
degree
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016507634A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016519107A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/033491 external-priority patent/WO2014169035A1/en
Publication of JP2016519107A publication Critical patent/JP2016519107A/ja
Publication of JP2016519107A5 publication Critical patent/JP2016519107A5/ja
Pending legal-status Critical Current

Links

JP2016507634A 2013-04-10 2014-04-09 Ｔｈ−３０２抗癌療法のための予測および応答のバイオマーカー Pending JP2016519107A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361810643P 2013-04-10 2013-04-10
US61/810,643 2013-04-10
PCT/US2014/033491 WO2014169035A1 (en) 2013-04-10 2014-04-09 Predictive and response biomarker for th-302 anti-cancer therapy

Publications (2)

Publication Number Publication Date
JP2016519107A JP2016519107A (ja) 2016-06-30
JP2016519107A5 true JP2016519107A5 (enExample) 2017-06-01

Family

ID=51689977

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016507634A Pending JP2016519107A (ja) 2013-04-10 2014-04-09 Ｔｈ−３０２抗癌療法のための予測および応答のバイオマーカー

Country Status (4)

Country Link
US (1) US20160296538A1 (enExample)
EP (1) EP2983591A4 (enExample)
JP (1) JP2016519107A (enExample)
WO (1) WO2014169035A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10071109B2 (en) 2013-11-06 2018-09-11 Molecular Templates, Inc. Predictive biomarker for hypoxia-activated prodrug therapy
EP3226869A4 (en) 2014-12-03 2018-07-18 Auckland UniServices, Ltd. Kinase inhibitor prodrug for the treatment of cancer
US11504075B2 (en) * 2017-12-20 2022-11-22 University Health Network System, methods, and devices for calculating hypoxic fraction and equilibration rate of small molecular weight tracers using dynamic imaging
JP7762796B2 (ja) 2021-08-27 2025-10-30 アセンタウィッツ ファーマシューティカルズ リミテッド Ｐａｒｐ阻害剤に耐性のある患者のｔｈ－３０２による治療
US20240366640A1 (en) 2021-08-27 2024-11-07 Ascentawits Pharmaceuticals, Ltd. Lyophilized formulation solution and lyophilized formulation, and method and use thereof
WO2023174319A1 (zh) 2022-03-15 2023-09-21 深圳艾欣达伟医药科技有限公司 治疗brca突变癌症患者的方法
CN119384281A (zh) 2022-04-15 2025-01-28 深圳艾欣达伟医药科技有限公司 使用th-302单药或联用parp抑制剂治疗癌症的方法
EP4529926A1 (en) 2022-05-23 2025-04-02 Ascentawits Pharmaceuticals, Ltd. Method for treating cancer by combining alkylating agent prodrug and cell cycle inhibitor
WO2024061346A1 (zh) 2022-09-22 2024-03-28 深圳艾欣达伟医药科技有限公司 乏氧激活的化合物在制备治疗癌症患者的药物中的用途
WO2024179467A1 (zh) * 2023-02-27 2024-09-06 深圳艾欣达伟医药科技有限公司 溶液、冻干制剂、冻干制剂单位包装、注射液及注射液配制方法
CN121646480A (zh) 2023-07-28 2026-03-10 深圳艾欣达伟医药科技有限公司 治疗p53基因突变或缺陷阴性癌症、肿瘤患者

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005508838A (ja) * 2001-03-23 2005-04-07 アフトン コーポレーション 膵癌の組合せ治療
US20070117784A1 (en) * 2005-03-04 2007-05-24 Novacea, Inc. Treatment of hyperproliferative diseases with anthraquinones
EP2350664B1 (en) * 2008-10-21 2021-05-19 ImmunoGenesis, Inc. Treatment of cancer using the hypoxia activated prodrug th-302 in combination with docetaxel or pemetrexed
WO2012006032A2 (en) * 2010-06-28 2012-01-12 Threshold Pharmaceuticals, Inc. Treatment of blood cancer
US20140010805A1 (en) * 2010-07-12 2014-01-09 Karen Curd Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer
US10357577B2 (en) * 2010-07-16 2019-07-23 Auckland Uniservices Limited Bacterial nitroreductase enzymes and methods relating thereto

Similar Documents

Publication Publication Date Title
ZA202107358B (en) Method for treating alzheimer's disease
BR112019008384A2 (pt) composição farmacêutica, processos para tratamento e seus usos
IN2015DN00450A (enExample)
MX2017014338A (es) Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina.
EA201591290A2 (ru) Креноланиб для лечения пролиферативных расстройств, связанных с мутацией flt3
CY1123501T1 (el) Χρηση ρεσλιζουμαμπης για τη θεραπευτικη αντιμετωπιση μετριου εως σοβαρου ηωσινοφιλικου ασθματος
CN111989095A (zh) 预防或治疗肿瘤疗法副作用的方法
PH12017500392A1 (en) Medical treatments based on anamorelin
JP2013536236A5 (enExample)
SMT202600102T1 (it) Guselkumab per l’uso nel trattamento della malattia di crohn con un regime di dosaggio
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
NZ754328A (en) Marker for acid sphingomyelinase disorders and uses thereof
IL264407A (en) Novel application of gzd824 and pharmaceutically acceptable salts thereof in treating diseases
JP2014201591A5 (enExample)
JP2019513151A5 (enExample)
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.
Estenkova et al. About the SPA and resort-based treatment of the patients with oncological diseases
Yamada Febrile neutropenia and peripheral nerve injuries: 3 case reports
Yu et al. CLINICAL INVESTIGATION OF THERAPEUTIC EFFECT OF HUO ZHEN AND HERBAL FUMIGANT IN TREATING ARTHRALGIA SYNDROME
Davies Acquired resistance in non-small cell lung cancer: case report
Stepanov et al. Experience of Vasonat usage in treatment of patients with chronic toxic hepatitis
Kilincalp Azathioprine/corticosteroid
CN302191919S (zh) 医用x射线乳腺摄影系统
CN302536694S (zh) 病人用界面组件